A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

24 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-05-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An individual's genetic make-up is known to determine their response to antipsychotic medication. Genetic markers that determine efficacy and side effects of medication may be identified and used to predict treatment outcome.

The study is a naturalistic study of routinely prescribed antipsychotics using outcome measures undertaken as part of the routine clinical care of the cohort. These clinical data are linked with genetic information obtained from DNA and RNA from blood samples undertaken as part of the study.

No alteration is made to the subjects treatment regime or medication.

The study is a two stage investigation:

* The first stage involves the collection of a databank of clinical information and blood samples for DNA and RNA extraction from patients treated with antipsychotic medication.
* The second stage is a molecular genetic investigation of treatment-related genetic factors that may contribute to response prediction and predisposition to side effects.

From these genetic studies pharmacogenetic prediction tests will be validated and/or developed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia

NCT05839613

Patients With Schizophrenia

NOT_YET_RECRUITING NA

Evaluating Pharmacogenomics-Based Pharmacotherapy in Real-World Settings for Schizophrenia

NCT06700967

Schizophenia Disorder

NOT_YET_RECRUITING

Clinical Utility of Pharmacogenomics of Psychotropic Medications

NCT03907124

Psychiatric Disorders Pain

WITHDRAWN PHASE4

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

NCT00178932

Schizophrenia Schizoaffective Disorder Bipolar Disorder +1 more

COMPLETED NA

Effect of Genotyping for CYP450 Polymorphisms Versus Intense Clinical Monitoring on Antipsychotic Drug Treatment

NCT00707382

Schizophrenia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Schizoaffective Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Olanzapine

Subjects treated with olanzapine as part of their routine clinical care

No interventions assigned to this group

Risperidone

Subjects treated with risperidone as part of their routine clinical care

No interventions assigned to this group

Quetiapine

Subjects treated with quetiapine as part of their routine clinical care

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent must be obtained
* DSM-IV diagnosis must be one of:

* schizophrenia
* schizophreniform
* schizoaffective
* delusional disorder
* brief reactive psychosis
* psychosis not otherwise specified
* Ethnic origin of both parents must be known
* A minimum of 6 weeks continuous treatment completed with the given antipsychotic, prescribed at least at minimum recommended doses
* Prospectively collected outcome data available (pre-treatment and after at least 6 weeks on treatment)

Exclusion Criteria

* Significant psychiatric or medical co-morbidity including history of:

* head injury with loss of consciousness
* seizures
* neurological disorder
* mental retardation (DSM-IV)
* drug or alcohol dependence (DSM-IV)
* serious physical illness e.g. malignancy, hepatic/renal insufficiency
* Concomitant psychotropic medication that may influence ratings
* Concomitant antipsychotics, antidepressants or mood stabilisers prescribed for \>2 weeks during the antipsychotic treatment period rated

Minimum Eligible Age

19 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No